Last updated: March 24, 2025
Sponsor: University of Missouri-Columbia
Overall Status: Active - Recruiting
Phase
1
Condition
Memory Loss
Speech Disorders
Communication Disorders
Treatment
Propranolol
Placebo
Magnetic Resonance Imaging (MRI)
Clinical Study ID
NCT06066710
2097152
Ages > 50 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age: 50 and older
- Primary Progressive Aphasia diagnosis
- Native English speaker
Exclusion
Exclusion Criteria:
- Unable to provide consent
- Taking alpha 2 agonists (clonidine and guanfacine)
- Other major psychological or neurological diagnosis
- Major head trauma that contributed to their condition
- Allergic reaction to adhesives
- Uncorrected vision/hearing impairments
- Diabetes
- Reactive airway disease
- Untreated hypothyroidism
- Bradyarrhythmia
- Unexplained syncope
- Pregnancy (assessed verbally on the days of MR imaging)
- Drugs that interact with propranolol, such as alpha 2 agonists
- Claustrophobia, inner ear implants, aneurysm or other surgical clips, metalforeign bodies in eye, pacemaker or other contraindication to MR scanning.Subjects with any implanted device that cannot be verified as MRI compliantwill be excluded.
Study Design
Total Participants: 30
Treatment Group(s): 3
Primary Treatment: Propranolol
Phase: 1
Study Start date:
January 13, 2025
Estimated Completion Date:
December 31, 2027
Connect with a study center
University of Missouri-Columbia
Columbia, Missouri 65212
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.